Clinical Trial

A Study of LY3971297 in Participants With Heart Failure

Not Yet Recruiting Phase 1
View on ClinicalTrials.gov →
Summary
The main purpose of this study is to assess how well LY3971297 is tolerated and what side effects may occur in participants with heart failure with preserved ejection fraction (HFpEF) and participants with heart failure with reduced ejection fraction (HFrEF). Blood tests will be performed to investigate how the body processes the study drug and how the study drug affects the body. For each participant, the study will last about 2 months and will include 1 inpatient visit lasting approximately 4 days and 5 outpatient visits.
Protocol Amendment History 3 changes
notable Trial sites expanded: 3 -> 10 locations 2026-06-17
notable Primary completion pushed: 2027-08 -> 2027-11 2026-06-17
minor Completion pushed: 2027-08 -> 2027-11 2026-06-17
Trial Details
NCT Number NCT07547540
Lead Sponsor Eli Lilly and Company
Conditions Heart Failure, Heart Failure, Diastolic, Heart Failure, Systolic
Enrollment 90 participants
Start Date 2026-08
Primary Completion 2027-11 (estimated)
Study Completion 2027-11 (estimated)
Updated on ClinicalTrials.gov 2026-08-10